This Article Free upon publication Full Text Full Text (PDF) All Versions of this Article: 53/5/860    most recent HYPERTENSIONAHA.108.128116v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Agarwal, R. Articles by Sinha, A. D. Search for Related Content PubMed PubMed Citation Articles by Agarwal, R. Articles by Sinha, A. D. Pubmed/NCBI databases Medline Plus Health Information Blood Pressure Medicines Dialysis Kidney Failure Related Collections Other hypertension

(Hypertension. 2009;53:860.)
© 2009 American Heart Association, Inc.

Original Articles

Cardiovascular Protection With Antihypertensive Drugs in Dialysis Patients

Systematic Review and Meta-Analysis

From the Division of Nephrology, Department of Medicine, Indiana University School of Medicine (R.A., A.D.S.); and Richard L. Roudebush Veterans’ Affairs Medical Center (R.A.), Indianapolis, Ind.

Correspondence to Rajiv Agarwal, VAMC, 111N, 1481 West 10th St, Indianapolis, IN 46202. E-mail ragarwal{at}iupui.edu

Epidemiological studies demonstrate that a lower blood pressure and decline in blood pressure over months or years are associated with higher mortality in dialysis patients. In contrast, randomized, controlled trials lack power to establish benefits of antihypertensive therapy. Patients on long-term dialysis participating in randomized, controlled trials and receiving antihypertensive drug therapy were the subject of this meta-analysis. Outcomes assessed were the hazard ratio of cardiovascular events and all-cause mortality in treated group compared with controls. Among 1202 patients who we identified in 5 studies, the overall benefit of antihypertensive therapy compared with the control or placebo group had a combined hazard ratio for cardiovascular events of 0.69 (95% CI: 0.56 to 0.84) using a fixed-effects model and 0.62 (95% CI: 0.45 to 0.86) using a random-effects model. In a sensitivity analysis, we found that the hypertensive group had a pooled hazard ratio of 0.49 (95% CI: 0.35 to 0.67), but when normotensives were included in the trial, lesser cardiovascular protection was seen (pooled hazard ratio of 0.86 [95% CI: 0.67 to 1.12]). Test for heterogeneity between hypertensive and "normotensive-included" groups was significant (P<0.006). Similar results were seen for risk ratio for death and cardiovascular events. There was evidence of publication bias based on Egger’s test and funnel plot. Randomized trials suggested a benefit of antihypertensive therapy among hemodialysis patients. Adequately powered randomized trials are required to confirm these observations, especially among those with hypertension.

Key Words: systematic review • cardiovascular events • reverse epidemiology • hypertension • hemodialysis • treatment

This article has been cited by other articles:

				D. J.A. Goldsmith and A. C. Covic Meta-Analysis of the Effects of Treating Blood Pressure on Cardiovascular Outcomes of Dialysis Patients Hypertension, July 1, 2009; 54(1): e6 - e6. [Full Text] [PDF]

				R. Agarwal and A. D. Sinha Response to Meta-Analysis of the Effects of Treating Blood Pressure on Cardiovascular Outcomes of Dialysis Patients Hypertension, July 1, 2009; 54(1): e7 - e7. [Full Text] [PDF]

				L. Siddiqi and P. J. Blankestijn Sympathetic Activity and Clinical Outcome in Dialysis Patients Hypertension, July 1, 2009; 54(1): e8 - e8. [Full Text] [PDF]

				R. Agarwal Response to Sympathetic Activity and Clinical Outcome in Dialysis Patients Hypertension, July 1, 2009; 54(1): e9 - e9. [Full Text] [PDF]